The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial
Authors:
Open Access
- 20 June 2023
- journal article
- research article
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 18 (1) , 1-14
Abstract
Summary: This study assessed whether vitamin K, given with oral bisphosphonate, calcium and/or vitamin D has an additive effect on fracture risk in post-menopausal women with osteoporosis. No difference in bone density or bone turnover was observed although vitamin K1 supplementation led to a modest effect on parameters of hip geometry. Purpose: Some clinical studies have suggested that vitamin K prevents bone loss and may improve fracture risk. The aim was to assess whether vitamin K supplementation has an additive effect on bone mineral density (BMD), hip geometry and bone turnover markers (BTMs) in post-menopausal women with osteoporosis (PMO) and sub-optimum vitamin K status receiving bisphosphonate, calcium and/or vitamin D treatment. Methods: We conducted a trial in 105 women aged 68.7[12.3] years with PMO and serum vitamin K1 ≤ 0.4 µg/L. They were randomised to 3 treatment arms; vitamin K1 (1 mg/day) arm, vitamin K2 arm (MK-4; 45 mg/day) or placebo for 18 months. They were on oral bisphosphonate and calcium and/or vitamin D. We measured BMD by DXA, hip geometry parameters using hip structural analysis (HSA) software and BTMs. Vitamin K1 or MK-4 supplementation was each compared to placebo. Intention to treat (ITT) and per protocol (PP) analyses were performed. Results: Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo. Following PP analysis and correction for covariates, there were significant differences in some of the HSA parameters at the intertrochanter (IT) and femoral shaft (FS): IT endocortical diameter (ED) (% change placebo:1.5 [4.1], K1 arm: -1.02 [5.07], p = 0.04), FS subperiosteal/outer diameter (OD) (placebo: 1.78 [5.3], K1 arm: 0.46 [2.23] p = 0.04), FS cross sectional area (CSA) (placebo:1.47 [4.09],K1 arm: -1.02[5.07], p = 0.03). Conclusion: The addition of vitamin K1 to oral bisphosphonate with calcium and/or vitamin D treatment in PMO has a modest effect on parameters of hip geometry. Further confirmatory studies are needed. Trial registration: The study was registered at Clinicaltrial.gov:NCT01232647.Keywords
Funding Information
- Royal Osteoporosis Society (191)
This publication has 36 references indexed in Scilit:
- Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy womenNutrition Journal, 2012
- Vitamin K Nutrition, Metabolism, and Requirements: Current Concepts and Future ResearchAdvances in Nutrition, 2012
- Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone qualityArthritis Research & Therapy, 2012
- An in vivo comparison of hip structure analysis (HSA) with measurements obtained by QCTOsteoporosis International, 2011
- High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatmentJournal of Bone and Mineral Metabolism, 2010
- Vitamin K Treatment Reduces Undercarboxylated Osteocalcin but Does Not Alter Bone Turnover, Density, or Geometry in Healthy Postmenopausal North American WomenJournal of Bone and Mineral Research, 2009
- Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Randomized Controlled TrialPLOS Medicine, 2008
- Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal womenJournal of Bone and Mineral Metabolism, 2008
- Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal womenOsteoporosis International, 2007
- Vitamin K2Inhibits Osteoclastic Bone Resorption by Inducing Osteoclast ApoptosisBiochemical and Biophysical Research Communications, 1996